Skip to main content

Table 1 Subject and tumor characteristics

From: Diffuse optical spectroscopic imaging reveals distinct early breast tumor hemodynamic responses to metronomic and maximum tolerated dose regimens

Variables

Treatment cohorts

Maximum tolerable dose (n = 35)

Metronomic dose (n = 19)

Overall (n = 54)

Age (years)

 Mean ± SD

51.3 ± 11.1

47.4 ± 10.8

49.9 ± 11.1

Tumor Size (cm)

 Mean ± SD

3.8 ± 1.9

3.0 ± 1.3

3.5 ± 1.7

Location

 Left

15 (43%)

10 (53%)

25 (46%)

 Right

20 (57%)

9 (47%)

29 (54%)

Histology

 IDC

31 (89%)

18 (95%)

49 (91%)

 ILC

4 (11%)

1 (5%)

5 (9%)

Receptor status

 ER

  −

13 (37%)

5 (26%)

18 (33%)

  +

21 (60%)

14 (74%)

35 (65%)

 PR

  −

15 (42%)

8 (42%)

23 (43%)

  +

19 (54%)

11 (58%)

30 (56%)

 HER2

  −

24 (69%)

14 (74%)

38 (70%)

  +

10 (29%)

5 (26%)

15 (28%)

  Unknown receptor (ER,PR,HER2)

1 (2%)

0

1 (2%)

Pathologic response

 Complete response

10 (29%)

5 (26%)

15 (28%)

 Partial response

15 (43%)

5 (26%)

20 (37%)

 No response

10 (29%)

9 (47%)

19 (35%)

Treatment

 AC

30 (86%)

0

30 (56%)

 AC + DTX

3 (9%)

0

3 (6%)

 Cb + DTX + Tr

1 (3%)

0

1 (2%)

 Cb + nPTX+Bev

0

14 (74%)

14 (26%)

 Cb + nPTX+Tr

0

5 (26%)

5 (9%)

 Pzb + DTX + Tr

1 (3%)

0

1 (2%)

Institute

 UC Irvine

29 (83%)

19 (100%)

48 (89%)

 Boston Medical Center

6 (17%)

0

6 (11%)

  1. Abbreviations: IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, ER estrogen receptor, PR progesterone receptor, HER2 Human Epidermal Growth Factor Receptor 2, AC adriamycin and cyclophosphamide, DTX docetaxel, Cb carboplatin, Tr trastuzumab, nPTX paclitaxel, Bev bevacizumab, Pzb pertuzumab